{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:44:04Z","timestamp":1789688644674,"version":"4.0.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T00:00:00Z","timestamp":1591574400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetes Ther"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s13300-020-00845-7","type":"journal-article","created":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T12:05:40Z","timestamp":1591617940000},"page":"1591-1603","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Glucagon Administration by Nasal and Intramuscular Routes in Adults With Type 1 Diabetes During Insulin-Induced Hypoglycaemia: A Randomised, Open-Label, Crossover Study"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1353-9043","authenticated-orcid":false,"given":"Jeffrey G.","family":"Suico","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"H\u00f6velmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brandon","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Sherr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Zijlstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Frier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leona","family":"Plum-M\u00f6rschel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,8]]},"reference":[{"key":"845_CR1","doi-asserted-by":"publisher","unstructured":"International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0 mmol\/l (54 mg\/dL) should be reported in clinical trials: a joint position statement of the American Diabetes Association and the European Association for the Study of Diabetes.Diabetes Care. 2017;40(1):155-7. https:\/\/doi.org\/10.2337\/dc16-2215.","DOI":"10.2337\/dc16-2215."},{"issue":"1","key":"845_CR2","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1002\/pdi.138","volume":"18","author":"G Harris","year":"2001","unstructured":"Harris G, Diment A, Sulway M, Wilkinson M. Glucagon administration\u2014underevaluated and undertaught. Practical Diabetes Int. 2001;18(1):22\u20135.","journal-title":"Practical Diabetes Int."},{"issue":"7","key":"845_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/dia.2016.0460","volume":"19","author":"JF Yale","year":"2017","unstructured":"Yale JF, Dulude H, Egeth M, et al. Faster use and fewer failures with needle-free nasal glucagon versus injectable glucagon in severe hypoglycemia rescue: A simulation study. Diabetes Technol Ther. 2017;19(7):423\u201332.","journal-title":"Diabetes Technol Ther."},{"issue":"1","key":"845_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/1932296814557518","volume":"9","author":"AE Pontiroli","year":"2015","unstructured":"Pontiroli AE. Intranasal glucagon: a promising approach for treatment of severe hypoglycemia. J Diabetes Sci Technol. 2015;9(1):38\u201343.","journal-title":"J Diabetes Sci Technol."},{"key":"845_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2147\/DMSO.S20633","volume":"4","author":"N Kedia","year":"2011","unstructured":"Kedia N. Treatment of severe diabetic hypoglycemia with glucagon: an underutilized therapeutic approach. Diabetes Metab Syndr Obes. 2011;4:337\u201346.","journal-title":"Diabetes Metab Syndr Obes."},{"issue":"9","key":"845_CR6","doi-asserted-by":"publisher","first-page":"12","DOI":"10.7748\/ncyp2011.11.23.9.12.c8790","volume":"23","author":"D Yardley","year":"2011","unstructured":"Yardley D, Lyddall A, Richardson J, et al. Glucagon injection for type 1 diabetes in children. Nurs Child Young People. 2011;23(9):12\u20138.","journal-title":"Nurs Child Young People."},{"key":"845_CR7","unstructured":"Glucagon (Glucagon for Injection). Eli Lilly and Company, Indianapolis, IN, USA. [Prescribing information], 2018. Available from: URL:https:\/\/uspl.lilly.com\/glucagon\/glucagon.html#pi. Accessed 01 May 2019."},{"issue":"2","key":"845_CR8","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc15-1498","volume":"39","author":"MR Rickels","year":"2016","unstructured":"Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover noninferiority study. Diabetes Care. 2016;39(2):264\u201370.","journal-title":"Diabetes Care."},{"key":"845_CR9","unstructured":"GlucaGen (glucagon for injection 1 mg\/mL). Novo Nordisk A\/S, Denmark. [Prescribing Information], 2018. Available from: https:\/\/www.novo-pi.com\/glucagenhypokit.pdf. Accessed 24 Apr 2019."},{"key":"845_CR10","doi-asserted-by":"crossref","unstructured":"Simons FE, Prenner BM, Finn A Jr Desloratadine Study Group. Efficacy and safety of desloratadine in the treatment of perennial allergic rhinitis. J Allergy Clin Immunol. 2003; 111(3):617-22.","DOI":"10.1067\/mai.2003.168"},{"issue":"22","key":"845_CR11","doi-asserted-by":"publisher","first-page":"2635","DOI":"10.1002\/(SICI)1097-0258(19981130)17:22<2635::AID-SIM954>3.0.CO;2-C","volume":"17","author":"RG Newcombe","year":"1998","unstructured":"Newcombe RG. Improved confidence intervals for the difference between binomial proportions based on paired data. Stat Med. 1998;17(22):2635\u201350.","journal-title":"Stat Med."},{"issue":"2","key":"845_CR12","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.numecd.2013.05.003","volume":"24","author":"A Ceriello","year":"2014","unstructured":"Ceriello A, Novials A, Ortega E, et al. Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutr Metab Cardiovasc Dis. 2014;24(2):116\u201323.","journal-title":"Nutr Metab Cardiovasc Dis."},{"issue":"5","key":"845_CR13","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1111\/dom.13278","volume":"20","author":"ER Seaquist","year":"2018","unstructured":"Seaquist ER, Dulude H, Zhang XM, et al. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting. Diabetes Obes Metab. 2018;20(5):1316\u201320.","journal-title":"Diabetes Obes Metab."},{"issue":"5","key":"845_CR14","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1111\/pedi.12668","volume":"19","author":"LC Deeb","year":"2018","unstructured":"Deeb LC, Dulude H, Guzman CB, et al. A phase 3 multicenter, open-label, prospective study designed to evaluate the effectiveness and ease of use of nasal glucagon in the treatment of moderate and severe hypoglycemia in children and adolescents with type 1 diabetes in the home or school setting. Pediatr Diabetes. 2018;19(5):1007\u201313. https:\/\/doi.org\/10.1111\/pedi.12668.","journal-title":"Pediatr Diabetes."}],"container-title":["Diabetes Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13300-020-00845-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13300-020-00845-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,27]],"date-time":"2022-10-27T02:32:36Z","timestamp":1666837956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13300-020-00845-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,8]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["845"],"URL":"https:\/\/doi.org\/10.1007\/s13300-020-00845-7","relation":{},"ISSN":["1869-6953","1869-6961"],"issn-type":[{"value":"1869-6953","type":"print"},{"value":"1869-6961","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,8]]},"assertion":[{"value":"15 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2020","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}